RIPK3 Protein (Receptor-Interacting Serine/Threonine Kinase 3)

RIPK3 Protein (Receptor-Interacting Serine/Threonine Kinase 3)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">RIPK3 Protein (Receptor-Interacting Serine/Threonine Kinase 3)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal kinase domain</td>
<td>Residues 1–286</td>
</tr>
<tr>
<td class="label">Activation loop</td>
<td>Contains Thr182</td>
</tr>
<tr>
<td class="label">RHIM domain</td>
<td>Residues 386–467</td>
</tr>
<tr>
<td class="label">C-terminal region</td>
<td>Residues 468–527</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>RIPK3</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>56.8 kDa (527 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Cytoplasm; translocates to membrane upon activation</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Restrictive — immune cells, neurons, some epithelial cells</td>
</tr>
<tr>
<td class="label">PDB structures</td>
<td>4M66 (kinase domain), 7Q5V (full-length)</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Kinase-independent functions</td>
<td>RIPK3 has scaffold roles beyond kinase activity; kinase inhibition may not fully block pathological RIPK3</td>
</tr>
<tr>
<td class="label">Alternative cell death

RIPK3 Protein (Receptor-Interacting Serine/Threonine Kinase 3)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">RIPK3 Protein (Receptor-Interacting Serine/Threonine Kinase 3)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal kinase domain</td>
<td>Residues 1–286</td>
</tr>
<tr>
<td class="label">Activation loop</td>
<td>Contains Thr182</td>
</tr>
<tr>
<td class="label">RHIM domain</td>
<td>Residues 386–467</td>
</tr>
<tr>
<td class="label">C-terminal region</td>
<td>Residues 468–527</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>RIPK3</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>56.8 kDa (527 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Location</td>
<td>Cytoplasm; translocates to membrane upon activation</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Restrictive — immune cells, neurons, some epithelial cells</td>
</tr>
<tr>
<td class="label">PDB structures</td>
<td>4M66 (kinase domain), 7Q5V (full-length)</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Kinase-independent functions</td>
<td>RIPK3 has scaffold roles beyond kinase activity; kinase inhibition may not fully block pathological RIPK3</td>
</tr>
<tr>
<td class="label">Alternative cell death</td>
<td>Blocking necroptosis may shift to apoptosis; dual targeting may be needed</td>
</tr>
<tr>
<td class="label">Selectivity over RIPK1</td>
<td>RIPK1 inhibitors exist but RIPK3-selective compounds are harder to develop due to structural similarity</td>
</tr>
<tr>
<td class="label">Blood-brain barrier penetration</td>
<td>Required for CNS diseases; challenging for kinase inhibitors</td>
</tr>
<tr>
<td class="label">Expression pattern</td>
<td>RIPK3 not expressed in all neurons; cell-type-specific targeting is needed</td>
</tr>
<tr>
<td class="label">Timing window</td>
<td>Necroptosis is rapid once activated; prophylactic or early-intervention strategies may be most effective</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">[RIPK1](/proteins/ripk1)</td>
<td>Necrosome partner; RHIM-mediated interaction</td>
</tr>
<tr>
<td class="label">[MLKL](/proteins/mlkl)</td>
<td>Phosphorylation substrate</td>
</tr>
<tr>
<td class="label">DAI/ZBP1</td>
<td>RHIM-containing DNA sensor</td>
</tr>
<tr>
<td class="label">TRIF</td>
<td>TLR3/4 adaptor with RHIM</td>
</tr>
<tr>
<td class="label">PGAM5</td>
<td>Mitochondrial phosphatase</td>
</tr>
<tr>
<td class="label">[Drp1](/proteins/drp1-protein)</td>
<td>Mitochondrial fission GTPase</td>
</tr>
<tr>
<td class="label">TAK1</td>
<td>Kinase; activates NF-κB</td>
</tr>
<tr>
<td class="label">Caspase-8</td>
<td>Cysteine protease</td>
</tr>
<tr>
<td class="label">FADD</td>
<td>Death domain adaptor</td>
</tr>
<tr>
<td class="label">CYLD</td>
<td>Deubiquitinase</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous across tissues</td>
</tr>
<tr>
<td class="label">Primary role</td>
<td>Scaffold → kinase; decision-maker</td>
</tr>
<tr>
<td class="label">Kinase activity</td>
<td>Moderate; modified by ubiquitination</td>
</tr>
<tr>
<td class="label">Inhibitors in clinic</td>
<td>Yes (GSK2982772, DNL747, SAR443820)</td>
</tr>
<tr>
<td class="label">Genetic knockout phenotype</td>
<td>Perinatal lethal (embryonic/day 1)</td>
</tr>
<tr>
<td class="label">Necrosome role</td>
<td>Initiator; recruits and activates RIPK3</td>
</tr>
<tr>
<td class="label">RHIM presence</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">TLR signaling</td>
<td>Canonical adaptor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">810 edges</a></td>
</tr>
</table>

Overview

Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) is the essential partner of [RIPK1](/proteins/ripk1) in executing [necroptosis](/entities/necroptosis), a programmed form of necrotic cell death. RIPK3 forms the necrosome core through RHIM domain-mediated interactions, leading to [MLKL](/proteins/mlkl) phosphorylation and plasma membrane disruption[@sun2012]. Unlike RIPK1, which functions as both a scaffold and a kinase, RIPK3 serves primarily as the kinase executioner of necroptosis[@ofengeim2013].

In neurodegenerative diseases, RIPK3 activation contributes to neuronal death and neuroinflammation. Unlike RIPK1, RIPK3 has more restricted expression but plays a critical role in necroptotic execution in vulnerable neuronal populations[@caccamo2017].

Protein Structure and Domains

Primary Structure

Kinase Domain Architecture

The RIPK3 kinase domain adopts a canonical protein kinase fold with:

• ATP-binding pocket: Occupies the cleft between the N- and C-lobes; coordinates Mg2+-ATP
• Activation loop: Contains key phosphorylation sites (Thr182, Ser227); conformational activation
• Activation segment: Rearrangement upon phosphorylation enables substrate access
• Unique structural features: The ATP-binding pocket of RIPK3 differs from RIPK1, enabling selective inhibitor development[@fischer2025]

RHIM Domain

The RHIM (RIP Homotypic Interaction Motif) is a ~20-residue sequence that mediates homotypic interactions between RIP family members:

• Core sequence: (I/V)-Q-x-L-x-G (residues 395–405)
• Amyloid formation: RHIM domains form cross-beta sheet structures in the necrosome, creating an amyloid-like signaling platform[@li2012]
• Structural role: Alternating RIPK1-RIPK3-RIPK1-RIPK3 filaments form the functional necrosome core
• Species conservation: Highly conserved across mammals; key for evolutionary function

Structural Insights

Structural studies have revealed:

• Necrosome architecture: Cryo-EM structures show RIPK1/RIPK3 alternating filaments forming a functional amyloid signaling complex[@li2012]
• Kinase activation: RIPK3 undergoes trans-autophosphorylation; Thr182 in the activation loop is critical
• MLKL interaction: RIPK3 binds MLKL through kinase domain-mediated contacts; Ser358 in MLKL is the primary phosphorylation site

Normal Function

Necroptosis Execution

RIPK3 is the central executor of necroptosis, executing the cell death program once initiated by upstream signals[@ofengeim2013]:

Alternative Functions Beyond Necroptosis

Beyond necroptosis, RIPK3 participates in several kinase-dependent and independent functions[@ofengeim2013]:

Kinase-dependent (necroptosis-independent):

• NF-κB activation: RIPK3 can activate the NF-κB pathway independently of necroptosis
• Inflammasome priming: May contribute to NLRP3 inflammasome activation
• Cell survival signaling: In some contexts, RIPK3 kinase activity promotes survival

• Apoptosis modulation: RIPK3 can interact with caspase-8 to regulate apoptosis
• Metabolic regulation: Influences mTOR signaling and cellular metabolism
• Innate immune signaling: RHIM-dependent sensing of viral nucleic acids

Physiological Roles

• Viral defense: Necroptosis limits viral replication — RIPK3-deficient mice are more susceptible to viral infection
• Tumor suppression: Necroptosis can be immunogenic, alerting the immune system to transformed cells
• Developmental cell death: RIPK3 knockout mice are viable but show increased susceptibility to viral and bacterial challenges[@wu2023]
• Intestinal homeostasis: Protective in models of inflammatory bowel disease

Role in Neurodegeneration

Alzheimer's Disease

RIPK3 activation is increasingly recognized as a contributor to AD pathology[@caccamo2017]:

Pathological findings:

• RIPK3 expression is elevated in AD brains, particularly in regions with high tau pathology
• RIPK3-positive cells co-localize with amyloid plaques and neurofibrillary tangles
• Microglial RIPK3 promotes a pro-inflammatory phenotype (M1 polarization)
• Necroptosis markers are present in degenerating neurons

• Aβ oligomers can directly activate RIPK3 through undefined mechanisms
• RIPK3 activation in microglia sustains neuroinflammation through cytokine release
• Neuronal RIPK3 contributes to both developmental and acute neuronal death

• RIPK3 knockout or knockdown reduces pathology and improves cognition in APP/PS1 mouse models[@caccamo2017]
• MLKL activation (downstream of RIPK3) is observed in AD brain tissue[@zhang2023]
• Inhibition of necroptosis reduces neuronal loss in organotypic slice cultures

Parkinson's Disease

RIPK3-mediated necroptosis contributes to dopaminergic neuron death in PD[@wang2023]:

Evidence from human tissue:

• RIPK3 and MLKL levels are elevated in the substantia nigra of PD patients
• Necroptosis markers correlate with disease severity
• Immunohistochemistry shows RIPK3 in dopaminergic neurons with α-synuclein inclusions

• MPTP toxicity activates RIPK3 in dopaminergic neurons; RIPK3 inhibition is neuroprotective
• 6-OHDA models show RIPK3 involvement in lesion formation
• α-synuclein preformed fibrils can activate necroptosis signaling

• α-synuclein aggregates may serve as DAMPs (damage-associated molecular patterns) triggering necrosome formation
• Mitochondrial dysfunction creates a permissive environment for necroptosis activation
• Neuroinflammation activates RIPK3 through TNF-α and TLR signaling in glia

Amyotrophic Lateral Sclerosis

Motor neurons are particularly susceptible to necroptosis[@re2014]:

Clinical relevance:

• RIPK3 and MLKL are activated in ALS spinal cord tissue
• SOD1 mutant mice show elevated necroptosis markers
• TDP-43 cytoplasmic aggregates trigger necroptotic pathways
• C9orf72 dipeptide repeats (DPRs) may activate RIPK3 signaling

• Necroptosis inhibition extends survival in SOD1G93A mouse models[@re2014]
• GSK'872 (RIPK3 inhibitor) protects motor neurons in culture
• Genetic deletion of RIPK1 or MLKL delays disease onset in ALS models

• High metabolic demand creates susceptibility to necroptosis activation
• Non-cell autonomous inflammation from glia activates RIPK3 in neurons
• Protein aggregation burden may prime the necrosome

Huntington's Disease

• RIPK3 activation is observed in striatal neurons in HD models and patient tissue
• Mutant huntingtin (mHTT) aggregates may trigger necroptotic signaling
• Synaptic dysfunction involves necroptotic effects on dendritic spines
• RIPK3 inhibition is protective in cellular and invertebrate HD models

Multiple Sclerosis and Demyelinating Diseases

• Oligodendrocytes undergo RIPK3-mediated necroptosis in MS and EAE models
• RIPK3 deficiency reduces demyelination and axonal loss in EAE
• Therapeutic targeting of RIPK3 may preserve myelin-producing cells

Stroke and Cerebral Ischemia

• Necrosome formation occurs rapidly after ischemia-reperfusion
• RIPK3 upregulation peaks hours to days post-stroke
• RIPK3-mediated secondary injury contributes to delayed neuronal death
• MLKL activation damages the blood-brain barrier through endothelial cell necroptosis

Therapeutic Targeting

RIPK3 Kinase Inhibitors

GSK'872 (GSK2399872A):[@kaiser2013]

• Potent and selective RIPK3 inhibitor (IC50 ~ 10 nM)
• Inhibits necroptosis in cell and animal models
• Cross-reacts with some RIPK1 activity at higher concentrations
• Research tool; not advanced to clinical development

• RIPK3-selective inhibitor with good kinome selectivity
• Protective in ischemia-reperfusion injury models
• Lower potency than GSK'872; useful for mechanistic studies

• Clinical-stage RIPK3 inhibitor
• Early development; pharmacokinetic properties under investigation
• Potential for neurological disease applications[@fischer2025]

• Several pharma companies have disclosed RIPK3 inhibitor programs
• Focus on achieving brain penetration for neurological indications
• Selectivity over RIPK1 is a key goal to avoid compound toxicity[@fischer2025]

Challenges in RIPK3 Targeting

Combination Approaches

• RIPK1 + RIPK3 dual inhibition: Complete necroptosis blockade (upstream + downstream)
• RIPK1 + caspase inhibition: Blocking both necroptosis and apoptosis convergence points
• RIPK3 + anti-inflammatory: Addressing both cell death and neuroinflammation
• Necroptosis + autophagy modulation: Targeting complementary cell death/survival pathways

Clinical Trial Landscape

• No RIPK3 inhibitors have reached late-stage clinical trials as of 2025
• Early-phase programs focus on acute neurological conditions (stroke, TBI) where timing is favorable
• Biomarker development for necroptosis activation is ongoing (plasma p-MLKL, RIPK3 activity assays)

Key Molecular Interactions

RIPK3 vs. RIPK1: Key Differences

See Also

• [Necroptosis](/entities/necroptosis) — the programmed necrosis pathway
• [RIPK1 Protein](/proteins/ripk1) — upstream partner in necrosome formation
• [MLKL Protein](/proteins/mlkl) — downstream executioner
• [Alzheimer's Disease](/diseases/alzheimers-disease) — RIPK3 role in AD pathology
• [Parkinson's Disease](/diseases/parkinsons-disease) — RIPK3 in dopaminergic neuron death
• [ALS](/diseases/als) — necroptosis in motor neuron degeneration
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — relationship with necroptosis
• [Neuroinflammation](/mechanisms/neuroinflammation) — RIPK3-driven inflammatory responses

External Links

• [UniProt: Q9Y572](https://www.uniprot.org/uniprot/Q9Y572)
• [PDB: 4M66](https://www.rcsb.org/structure/4M66)
• [PDB: 7Q5V](https://www.rcsb.org/structure/7Q5V)
• [PubMed: RIPK3 necroptosis neurology](https://pubmed.ncbi.nlm.nih.gov/?term=ripk3+necroptosis+neurodegeneration)

Pathway Diagram

The following diagram shows the key molecular relationships involving RIPK3 Protein (Receptor-Interacting Serine/Threonine Kinase 3) discovered through SciDEX knowledge graph analysis: